SCHEMBL17540894

SCHEMBL17540894

Cc1ccc2cccc(NC(=O)c3ccc(Br)s3)c2n1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.60
TSHR P16473 1/20 0.60
HSD17B10 Q99714 1/20 0.60
POLB P06746 4/20 0.57
MAPT P10636 4/20 0.57
GAA P10253 1/20 0.57
NFKBIA P25963 1/20 0.57
RELA Q04206 1/20 0.57
MEN1 O00255 3/20 0.53
KMT2A Q03164 3/20 0.53
CASP3 P42574 1/20 0.53
SENP8 Q96LD8 1/20 0.53
SENP7 Q9BQF6 1/20 0.53
SENP6 Q9GZR1 1/20 0.53
TP53 P04637 3/20 0.51
ALOX12 P18054 1/20 0.51
KDM4E B2RXH2 1/20 0.48
NPC1 O15118 1/20 0.48
HPGD P15428 1/20 0.48
PPARG P37231 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29831277 0.87 MAPT (0.60) ALDH1A1TSHRHSD17B10POLBMAPT
SCHEMBL17552220 0.87 MAPT (0.60) ALDH1A1TSHRHSD17B10POLBMAPT
SCHEMBL29911193 0.86 MAPT (0.58) ALDH1A1TSHRHSD17B10POLBMAPT
SCHEMBL17552222 0.86 MAPT (0.58) ALDH1A1TSHRHSD17B10POLBMAPT
SCHEMBL29911281 0.85 ALDH1A1 (0.57) ALDH1A1TSHRHSD17B10POLBMAPT
SCHEMBL17552224 0.85 ALDH1A1 (0.57) ALDH1A1TSHRHSD17B10POLBMAPT
SCHEMBL19422868 0.84 MMP2 (0.50) ALDH1A1POLBMEN1KMT2ACASP3
SCHEMBL29831046 0.84 MMP2 (0.50) ALDH1A1POLBMEN1KMT2ACASP3
SCHEMBL17552211 0.83 ALDH1A1 (0.58) ALDH1A1TSHRHSD17B10POLBMAPT
SCHEMBL29911220 0.83 ALDH1A1 (0.58) ALDH1A1TSHRHSD17B10POLBMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250248990-A1 QUINOLINES THAT MODULATE SERCA AND THEIR USE FOR TREATING DISEASE NEURODON CORPORATION 2025-08-07 US disclosed
US-12144806-B2 Quinolines that modulate SERCA and their use for treating disease NEURODON CORPORATION (US) 2024-11-19 US disclosed
US-20240277694-A1 QUINOLINES THAT MODULATE SERCA AND THEIR USE FOR TREATING DISEASE NEURODON CORPORATION 2024-08-22 US disclosed
US-11992487-B2 Quinolines that modulate SERCA and their use for treating disease NEURODON CORPORATION (US) 2024-05-28 US disclosed
EP-4037685-B9 QUINOLINE THAT MODULATE SERCA AND ITS USE FOR TREATING DISEASE NEURODON CORP (US) 2024-03-06 EP disclosed
US-20240016793-A1 QUINOLINES THAT MODULATE SERCA AND THEIR USE FOR TREATING DISEASE NEURODON CORPORATION 2024-01-18 US disclosed
US-20240016793-A1 QUINOLINES THAT MODULATE SERCA AND THEIR USE FOR TREATING DISEASE NEURODON CORPORATION 2024-01-18 US disclosed
US-11827626-B2 Quinolines that modulate SERCA and their use for treating disease NEURODON CORPORATION (US) 2023-11-28 US disclosed
US-11827626-B2 Quinolines that modulate SERCA and their use for treating disease NEURODON CORPORATION (US) 2023-11-28 US disclosed
EP-4037685-B1 QUINOLINE THAT MODULATE SERCA AND ITS USE FOR TREATING DISEASE NEURODON CORP (US) 2023-09-20 EP disclosed
US-20230285382-A1 QUINOLINES THAT MODULATE SERCA AND THEIR USE FOR TREATING DISEASE NEURODON CORPORATION 2023-09-14 US disclosed
CN-116744928-A Quinolines modulating SERCA and their use for treating diseases 神经元公司 2023-09-12 CN disclosed
US-11730729-B2 Quinolines that modulate SERCA and their use for treating disease NEURODON CORPORATION (US) 2023-08-22 US disclosed
US-11730729-B2 Quinolines that modulate SERCA and their use for treating disease NEURODON CORPORATION (US) 2023-08-22 US disclosed
WO-2022020261-A9 QUINOLINES THAT MODULATE SERCA AND THEIR USE FOR TREATING DISEASE NEURODON CORPORATION (US) 2022-09-09 WO disclosed
US-20220016108-A1 QUINOLINES THAT MODULATE SERCA AND THEIR USE FOR TREATING DISEASE NEURODON CORPORATION 2022-01-20 US disclosed
US-20170281611-A1 QUINOLINES AND THEIR USE FOR TREATING ENDOPLASMIC RETICULUM STRESS-CAUSED DISEASES EIGER BIOPHARMACEUTICALS, INC. (US) 2017-10-05 US disclosed
WO-2016032569-A1 QUINOLINES AND THEIR USE FOR TREATING ENDOPLASMIC RETICULUM STRESS-CAUSED DISEASES CELLADON CORPORATION (US) 2016-03-03 WO disclosed
WO-2016032569-A1 QUINOLINES AND THEIR USE FOR TREATING ENDOPLASMIC RETICULUM STRESS-CAUSED DISEASES CELLADON CORPORATION (US) 2016-03-03 WO disclosed
US-9029407-B2 Aminothiazole modulators of beta-3-adrenoreceptor AUSPEX PHARMACEUTICALS, INC. (US) 2015-05-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230285382-A1 QUINOLINES THAT MODULATE SERCA AND THEIR USE FOR TREATING DISEASE ATP2A1, ATP2A3, ATP2A2 ALDH1A1 1661/4885TSHR 3549/4885HSD17B10 1998/4885
US-20170281611-A1 QUINOLINES AND THEIR USE FOR TREATING ENDOPLASMIC RETICULUM STRESS-CAUSED DISEASES ATP2A1, ATP2A3, ATP2A2 ALDH1A1 2843/4885TSHR 4322/4885HSD17B10 1363/4885
US-11992487-B2 Quinolines that modulate SERCA and their use for treating disease ATP2A1, ATP2A3, ATP2A2 ALDH1A1 1661/4885TSHR 3549/4885HSD17B10 1998/4885
US-12144806-B2 Quinolines that modulate SERCA and their use for treating disease ATP2A1, ATP2A3, ATP2A2 ALDH1A1 1661/4885TSHR 3549/4885HSD17B10 1998/4885
US-20250248990-A1 QUINOLINES THAT MODULATE SERCA AND THEIR USE FOR TREATING DISEASE ATP2A1, ATP2A3, ATP2A2 ALDH1A1 1661/4885TSHR 3549/4885HSD17B10 1998/4885
US-11730729-B2 Quinolines that modulate SERCA and their use for treating disease ATP2A1, ATP2A3, ATP2A2 ALDH1A1 1661/4885TSHR 3549/4885HSD17B10 1998/4885
US-11827626-B2 Quinolines that modulate SERCA and their use for treating disease ATP2A1, ATP2A3, ATP2A2 ALDH1A1 1661/4885TSHR 3549/4885HSD17B10 1998/4885
US-20240277694-A1 QUINOLINES THAT MODULATE SERCA AND THEIR USE FOR TREATING DISEASE ATP2A1, ATP2A3, ATP2A2 ALDH1A1 1661/4885TSHR 3549/4885HSD17B10 1998/4885
US-20220016108-A1 QUINOLINES THAT MODULATE SERCA AND THEIR USE FOR TREATING DISEASE ATP2A1, ATP2A3, ATP2A2 ALDH1A1 1661/4885TSHR 3549/4885HSD17B10 1998/4885
US-20240016793-A1 QUINOLINES THAT MODULATE SERCA AND THEIR USE FOR TREATING DISEASE ATP2A1, ATP2A3, ATP2A2 ALDH1A1 1661/4885TSHR 3549/4885HSD17B10 1998/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.